New York, March 2, 2026, 08:27 EST — Premarket
BioCryst Pharmaceuticals slipped 2.9% to $8.50 before the bell on Monday, paring recent gains after new clinical data emerged around its hereditary angioedema pipeline.
Timing is key here. The next phase for BioCryst depends on its ability to expand the HAE franchise past ORLADEYO—the once-daily pill currently footing most of the bill.
HAE triggers abrupt swelling episodes, and these days, convenience rivals effectiveness in the battle to prevent them. BioCryst is wagering that stretching dosing intervals will help its candidate carve out space in a crowded field of injectable preventives.
BioCryst, in a poster presented at the American Academy of Allergy, Asthma & Immunology meeting in Philadelphia, reported that its long-term ALPHA-SOLAR open-label study with navenibart — an investigational anti-plasma kallikrein antibody intended for dosing every three or six months — brought mean monthly HAE attack rates down to 0.16 from a baseline of 2.23. That’s about a 91% drop. The data covered 29 participants tracked over an average of 12.5 months. Most common treatment-related side effect: injection-site reactions. One patient discontinued after developing invasive ductal breast carcinoma, classified as a serious adverse event not attributed to the treatment. No treatment-related serious adverse events were reported, according to the poster.
BioCryst on Feb. 26 posted full-year 2025 ORLADEYO net revenue totaling $601.8 million and kept its 2026 revenue outlook for the drug between $625 million and $645 million. “We entered 2026 with strong momentum,” President and CEO Charlie Gayer said in the announcement, which also noted that the navenibart Phase 3 program should back a regulatory filing before the close of 2027. GlobeNewswire
Now, traders are piecing things together. Interim updates and conference posters only go so far in biotech—what really counts for valuation is late-stage follow-through. Details on enrollment speed, trial setup, or where navenibart might slot in next to a daily oral alternative are poised to outweigh whatever a lone chart says.
Competition isn’t going anywhere. Takeda’s Takhzyro and CSL’s Haegarda have dominated the injectable prevention landscape, but with fresh options on the table, payers are pushing back harder in negotiations.
There’s a hitch, though. These ALPHA-SOLAR results? Interim, open-label—no blinding here, so you don’t get that strict comparison, and small sample sizes often look good until Phase 3 brings reality. On top of that, pricing pressure, softer ORLADEYO growth, or if the pivotal trial stumbles, any of those could hit the downside.
BioCryst is on the agenda for Tuesday at the T.D. Cowen 46th Annual Health Care Conference in Boston, with its presentation set for 9:10 a.m. ET. Investors looking for more detail around 2026 execution and updates on navenibart milestones will be watching closely.
